SCHEMBL614058

SCHEMBL614058

CC(=O)OC1(CNC(=O)OC(C)OC(=O)C(C)C)CCCCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3400869 1.00
SCHEMBL3808910 0.92 CTSK (0.30)
SCHEMBL6880645 0.88
SCHEMBL3809933 0.87
SCHEMBL3809432 0.86 PRKCA (0.30)
SCHEMBL3819375 0.86
SCHEMBL3832131 0.85 LMNA (0.34)
SCHEMBL3402103 0.84
SCHEMBL3817236 0.84 CTSL (0.31)
SCHEMBL3813044 0.83 P2RX7 (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2013151796-A1 CLONIDINE COMPOUNDS IN A BIODEGRADABLE MATRIX WARSAW ORTHOPEDIC, INC. (US) 2013-10-10 WO claimed
US-8299291-B2 Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs XENOPORT, INC. (US) 2012-10-30 US claimed
WO-2012075451-A2 CLONIDINE AND GABA COMPOUNDS IN A BIODEGRADABLE POLYMER CARRIER WARSAW ORTHOPEDIC, INC. (US) 2012-06-07 WO claimed
EP-2403481-A1 ORAL DOSAGE FORMS HAVING A HIGH LOADING OF A GABAPENTIN PRODRUG XenoPort, Inc. (US) 2012-01-11 EP claimed
WO-2010102252-A1 ORAL DOSAGE FORMS HAVING A HIGH LOADING OF A GABAPENTIN PRODRUG XENOPORT, INC. (US) 2010-09-10 WO claimed
US-20100087667-A1 METHODS OF SYNTHESIZING 1-(ACYLOXY)-ALKYL CARBAMATE PRODRUGS XENOPORT, INC. (US) 2010-04-08 US claimed
EP-2086530-A1 USE OF GABAPENTIN AND PREGABALIN PRODRUGS FOR TREATING TINNITUS Xenoport, Inc. (US) 2009-08-12 EP claimed
WO-2008157408-A2 USE OF PRODRUGS OF GABA ANALOGS, ANTISPASTICITY AGENTS, AND PRODRUGS OF GABA B RECEPTOR AGONISTS FOR TREATING SPASTICITY XENOPORT, INC. (US) 2008-12-24 WO claimed
WO-2008060572-A1 USE OF GABAPENTIN AND PREGABALIN PRODRUGS FOR TREATING TINNITUS XENOPORT, INC. (US) 2008-05-22 WO claimed
EP-1677767-A4 CRYSTALLINE FORM OF GAMMA-AMINOBUTYRIC ACID ANALOG XENOPORT INC (US) 2008-03-05 EP claimed
EP-1811986-A1 GABAPENTIN PRODRUG SUSTAINED RELEASE ORAL DOSAGE FORMS Xenoport, Inc. (US) 2007-08-01 EP claimed
WO-2007027477-A2 TREATING VULVODYNIA USING PRODRUGS OF GABA ANALOGS XENOPORT, INC. (US) 2007-03-08 WO claimed
EP-1677767-A2 CRYSTALLINE FORM OF GAMMA-AMINOBUTYRIC ACID ANALOG Xenoport, Inc. (US) 2006-07-12 EP claimed
WO-2006050514-A1 GABAPENTIN PRODRUG SUSTAINED RELEASE ORAL DOSAGE FORMS XENOPORT, INC. (US) 2006-05-11 WO claimed
WO-2005037784-A2 CRYSTALLINE FORM OF GAMMA-AMINOBUTYRIC ACID ANALOG XENOPORT, INC. (US) 2005-04-28 WO claimed
CN-118255707-A Preparation method of gabapentin enroacalcet related substances 江苏百奥信康医药科技有限公司 2024-06-28 CN disclosed
CN-115844834-A Gabapentin Enacarbo sustained-release dry suspension and preparation method thereof 江苏百奥信康医药科技有限公司 2023-03-28 CN disclosed
WO-2005027850-A2 TREATING OR PREVENTING RESTLESS LEGS SYNDROME USING PRODRUGS OF GABA ANALOGS XENOPORT, INC. (US) 2005-03-31 WO disclosed
WO-2005025562-A1 TREATING AND/OR PREVENTING URINARY INCONTINENCE USING PRODRUGS OF GABA ANALOGS XENOPORT, INC. (US) 2005-03-24 WO disclosed
WO-2004089289-A2 TREATING OR PREVENTING HOT FLASHES USING PRODRUGS OF GABA ANALOGS XENOPORT, INC. (US) 2004-10-21 WO disclosed